LNX 231
Alternative Names: LNX-231Latest Information Update: 10 Jul 2024
At a glance
- Originator Lunan Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia